Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE1 first-line randomized platform study in metastatic renal cell carcinoma
2023-503317-29-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, nivolumab, ipilimumab, axitinib, lenvatinib and 1 more in renal cell carcinoma (RCC) (4 arms), sponsored by Gustave Roussy. Primary endpoints: Overall survival, Progression-free survival and 6 more. Planned start Apr 2024; status: authorised.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-503317-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503317-29-00.